Title : Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus.

Pub. Date : 2019 Oct

PMID : 30688048






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In addition, change in apoB/A1 ratio (-0.44+-0.16 in the rosuvastatin group and -0.47+-0.25 in the rosuvastatin/ezetimibe group, P=0.58) did not differ between the two groups. Rosuvastatin Calcium apolipoprotein B Homo sapiens
2 In addition, change in apoB/A1 ratio (-0.44+-0.16 in the rosuvastatin group and -0.47+-0.25 in the rosuvastatin/ezetimibe group, P=0.58) did not differ between the two groups. Rosuvastatin Calcium apolipoprotein B Homo sapiens
3 CONCLUSION: A 6-week combination therapy of low-dose rosuvastatin and ezetimibe showed LDL-C, apoB, and apoB/A1 ratio reduction comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus. Rosuvastatin Calcium apolipoprotein B Homo sapiens
4 CONCLUSION: A 6-week combination therapy of low-dose rosuvastatin and ezetimibe showed LDL-C, apoB, and apoB/A1 ratio reduction comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus. Rosuvastatin Calcium apolipoprotein B Homo sapiens